Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Medical technology & services

Bloom Health Partners closes second tranche of its previously announced non-brokered private placement for gross proceeds of C$554,000

Combined with the first tranche of the offering, the company has sold 7,920,000 units for aggregate gross proceeds of C$1,584,000

Bloom Health Partners Inc (CSE:BLMH, OTCQB:BLMHF) said it has closed the second tranche of its previously announced non-brokered private placement offering and has issued 2,770,000 units at a price of $0.20 each for gross proceeds of C$554,000.

Combined with the first tranche of the offering, the company has sold 7,920,000 units for aggregate gross proceeds of C$1,584,000.

The net proceeds of the offering will be used by the company for ongoing working capital and corporate development.

READ: Bloom Health Partners closes initial tranche of private placement raising $1.03M in gross proceeds

The units in the offering are comprised of one common share in the capital of the company and one-half of a transferable common share purchase warrant. Each whole warrant entitles the holder to acquire one additional common share at a price of $0.30 each until July 18, 2023.

In connection with closing the second tranche of the offering, the company paid C$32,640 and issued 163,200 warrants, exercisable at a price of $0.30 per each until July 18, 2023, to an arms-length party who assisted in introducing subscribers.

All securities issued in connection with the offering are subject to a statutory hold period until November 19, 2022, in accordance with applicable securities laws.

Investor Relations engagement

Bloom Health also announced that its board of directors has approved a change in the duties of an existing consultant, Spiro Kletas, to include advising the company on shareholder communications and financing strategy.

Kletas is presently compensated at a rate of $6,000 per month, and will continue at this rate. In consideration for his additional duties, he has also been granted 150,000 incentive stock options, vesting over a twelve-month period and exercisable at a price of $0.40 until July 5, 2025.

Bloom Health is a global platform for healthcare security, diagnostic testing and occupational health-tech. Its mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models.

The company offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Its stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

Contact the author at jon.hopkins@proactiveinvestors.com

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK